论文部分内容阅读
Ｆｒａｘｉｐａｒｉｎ是一种小分子量肝素。研究结果表明，Ｆｒａｘｉｐａｒｉｎ可刺激鼠巨核细胞－血小板系统增生。在体外试验，Ｆｒａｘｉｐａｒｉｎ可刺激鼠巨核系祖细胞的增生和巨核细胞的成熟，其刺激增生作用与其中和血小板第４因子的作用有关。鼠的体内研究结果进一步证实Ｆｒａｘｉｐａｒｉｎ对巨核细胞有刺激增生作用。小剂量Ｆｒａｘｉｐａｒｉｎ也有刺激作用，但其刺激增生作用持续时间较短。Ｆｒａｘｉｐａｒｉｎ注射后５天，血小板计数较对照组略有升高，但无统计学意义。无论体内或体外，Ｆｒａｘｉｐａｒｉｎ对ＣＦＵ－ＧＭ均无刺激作用。
Fraxiparin is a small molecular weight heparin. The results show that, Fraxiparin can stimulate rat megakaryocyte - platelet system hyperplasia. In vitro, Fraxiparin stimulates the proliferation of megakaryocyte progenitor cells and the maturation of megakaryocytes, which stimulates proliferation and correlates with its role in neutralizing platelet factor 4. In vivo studies in mice further confirmed that Fraxiparin has a stimulatory effect on megakaryocytes. Small doses of Fraxiparin also have stimulating effects, but they stimulate proliferation for a short duration. Five days after Fraxiparin injection, platelet counts slightly increased compared with the control group, but not statistically significant. Fraxiparin has no effect on CFU-GM both in vivo and in vitro.